Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Expired

Tissue Chips in Space 2.0: Translational Multi-Organ Tissue Chip Systems for Drug Efficacy, Toxicity Testing, and Personalized Medicine in Human Health, Aging and Associated Diseases (UG3/UH3 Clinical Trial Not Allowed)

National Institutes of Health

The purpose of this Notice of Funding Opportunity (NOFO) is to develop multi-organ automated microphysiological systems (MPS) for studying the effects of microgravity conditions on human body in low Earth orbit at the International Space Station National Laboratory (ISS-NL). This program will provide insights on human patho(physiology), especially aging-related functional decline and age-related diseases. The multi-organ MPS configuration will allow better modeling of the whole organism. Improved automation with extended longevity of MPS will facilitate longer experiments in space and the collection of more physiologically relevant data. The inclusion of samples representing the broad spectrum of diversity in the human population will allow for better modeling of aging progression and development of interventions. Funds from the NIH will be made available through the UG3/UH3 cooperative agreement mechanism. During the initial UG3 phase, support will be provided to develop robust complex organ systems, which can manifest the hallmarks of human age-related tissue and organ dysfunction and recapitulate the progression of aging-associated diseases when exposed to prolonged microgravity. The multi-organ integrated systems will be validated and tested on the ground to assess capability of chips to sustain flight-related stresses and to provide evidence of the functional utility of the proposed models for experiments at the ISS-NL. Following administrative review, the UH3 phase will build upon successful UG3-developed models to facilitate the assessment on the ISS-NL of the hallmarks of aging, biomarkers of associated diseases, bioavailability, efficacy, and toxicity of therapeutic agents. It is anticipated that these studies will lead to the identification of novel treatment mechanisms through better understanding of age-related disease biology, pathways and mechanisms underlying age-related tissue and organ functional decline and age-related diseases, drug screening, assessment of candidate therapies for efficacy and safety. This program will establish the pre-clinical foundation to inform clinical studies on Earth.

Deadlines:

Letter of Intent Due Date(s): September 16, 2024
Application Due Date: October 18, 2024

RFA-TR-24-025 Expiration Date October 19, 2024

Specialties

Medical

Medical - Clinical Science

Medical - Basic Science

Medical - Translational

Eligibility Requirements

Sponsor Details

Sponsor Institute/Organizations: National Institutes of Health

Sponsor Type:

Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity